These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24841364)

  • 1. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers.
    Medellín-Garibay SE; Milán-Segovia Rdel C; Magaña-Aquino M; Portales-Pérez DP; Romano-Moreno S
    J Pharm Pharmacol; 2014 Oct; 66(10):1421-8. PubMed ID: 24841364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.
    Milán Segovia RC; Domínguez Ramírez AM; Jung Cook H; Magaña Aquino M; Vigna Pérez M; Brundage RC; Romano Moreno S
    J Clin Pharm Ther; 2013 Feb; 38(1):56-61. PubMed ID: 23167603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
    Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients.
    Chang MJ; Chae JW; Yun HY; Lee JI; Choi HD; Kim J; Park JS; Cho YJ; Yoon HI; Lee CT; Shin WG; Lee JH
    Tuberculosis (Edinb); 2015 Jan; 95(1):54-9. PubMed ID: 25482224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of oral rifampicin in AIDS patients.
    Jaruratanasirikul S
    J Med Assoc Thai; 1998 Jan; 81(1):25-8. PubMed ID: 9470318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs.
    Garcia Contreras L; Sung J; Ibrahim M; Elbert K; Edwards D; Hickey A
    Mol Pharm; 2015 Aug; 12(8):2642-50. PubMed ID: 25942002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.
    Stott KE; Pertinez H; Sturkenboom MGG; Boeree MJ; Aarnoutse R; Ramachandran G; Requena-Méndez A; Peloquin C; Koegelenberg CFN; Alffenaar JWC; Ruslami R; Tostmann A; Swaminathan S; McIlleron H; Davies G
    J Antimicrob Chemother; 2018 Sep; 73(9):2305-2313. PubMed ID: 29701775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited sampling strategies to predict the area under the concentration-time curve for rifampicin.
    Medellín-Garibay SE; Correa-López T; Romero-Méndez C; Milán-Segovia RC; Romano-Moreno S
    Ther Drug Monit; 2014 Dec; 36(6):746-51. PubMed ID: 24784025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.
    Medellin-Garibay SE; Huerta-García AP; Rodríguez-Báez AS; Magaña-Aquino M; Ortiz-Álvarez A; Portales-Pérez DP; Milán-Segovia RDC; Romano-Moreno S
    Tuberculosis (Edinb); 2020 Sep; 124():101982. PubMed ID: 32810723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Rifampicin in Chinese Patients With Pulmonary Tuberculosis.
    Jing Y; Zhu LQ; Yang JW; Huang SP; Wang Q; Zhang J
    J Clin Pharmacol; 2016 May; 56(5):622-7. PubMed ID: 26387492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some plasma and saliva pharmacokinetics parameters of rifampicin in the presence of pefloxacin.
    Orisakwe OE; Akunyili DN; Agbasi PU; Ezejiofor NA
    Am J Ther; 2004; 11(4):283-7. PubMed ID: 15266220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.
    Conte JE; Golden JA; Kipps JE; Lin ET; Zurlinden E
    Clin Pharmacokinet; 2004; 43(6):395-404. PubMed ID: 15086276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers.
    Pargal A; Rani S
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):70-9. PubMed ID: 11263520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
    Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.